Archived explainer. For the current picture see today's KOD page.
Why Is KODIAK SCIENCES INC (KOD) Stock Up Today?
By the Top Tier Newswire AI Desk · September 28, 2026 at 10:39 PM ET · reviewed against 24 wire stories
KODIAK SCIENCES INC (KOD) is up +177.96% in the latest session. Our newswire has captured 24 stories on KOD across 14 sources in the last 36 hours, with AI sentiment reading bullish (avg 65/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
Kodiak Sciences Inc. (KOD) surged 177.96% to $89.92 on Monday, driven by strong Phase 3 DAYBREAK trial results for its wet AMD treatments, Zenkuda and tabirafusp-ted. The stock opened with a 63.5% gap up and reached an intraday high of $95.77. The rally was fueled by data showing the drugs matched Regeneron’s Eylea in primary endpoints, with Zenkuda demonstrating extended dosing intervals. Analysts at Jefferies and LifeSci Capital raised price targets, while UBS also increased its target to $120.
What Happened
Kodiak’s stock spiked after the release of topline data from the DAYBREAK trial, which demonstrated the efficacy of its long-acting eye medications. Zenkuda and tabirafusp-ted met primary endpoints, showing comparable performance to Eylea, a leading treatment in the wet AMD market. The results were highlighted in a slide deck published by the company on September 28, 2026. The positive data led to a sharp selloff in competitors such as Ocupher (OCUL), as investors shifted capital to Kodiak. Jefferies raised its price target for KOD to $112 from $56, while LifeSci Capital increased its target to $145 from $85. UBS also raised its target to $120 and maintained a Buy rating.
Retail traders on social platforms noted the stock’s 150% jump, attributing it to the trial success. The stock closed the session at $88.11, with 27.9 million shares traded, far above its 3-month average.
What The Data Shows
The stock printed a fresh 52-week high on September 28 and has gained 140.1% over the last eight sessions. Intraday volume reached 38.3 times the 3-month average, indicating strong institutional and retail interest. Call options saw no notable premium, while put options totaled $2.5 million in premium, with the largest single print at $1.9 million. The stock’s beta of 2.18 suggests high volatility, and its current price of $88.11 is well above its 52-week range of $10.94 to $47.84.
What To Watch
Kodiak Sciences has no upcoming earnings date, but investors will monitor the breadth of analyst coverage and any further updates from competitors in the wet AMD space.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
Jefferies cuts Kodiak Sciences stock price target on valuation review
Jefferies cuts Kodiak Sciences stock price target on valuation review
13h agoStocktwits NewsBEARISH 32General
OCUL Stock Suffers Sharpest Drop Since February As KOD And FDMT Post Updates On Their Wet AMD Drugs
OCUL’s selloff on Monday was spurred by clinical updates from competitors on their wet AMD treatments.
14h agoThe FlyBULLISH 69Analyst
Kodiak Sciences price target raised to $145 from $85 at LifeSci Capital
14h agoCNBCNEUTRAL 50General
Stocks making the biggest moves midday: MongoDB, Boeing, Kodiak Sciences, Roblox, Nvidia & more
Here are some of the companies making headlines in midday trading.
14h agoSeeking AlphaBULLISH 56Product/PR
Kodiak Sciences Inc. (KOD) Discusses DAYBREAK Topline Data and Primary Endpoint Results - Slideshow
2026-09-28. The following slide deck was published by Kodiak Sciences Inc.
14h agoThe FlyBULLISH 68General
Kodiak Sciences rises 161.9%
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →